摘要
目的:为前列地尔脂微球注射剂(Lipo-PGE1)的合理应用和监管提供依据。方法:以来源于全国159家医院医院信息系统中使用Lipo-PGE1的成年住院患者为研究对象,基于频数统计法对Lipo-PGE1的临床使用人群、临床诊断和平均日剂量进行研究。结果:共71 687例成年住院患者纳入统计,使用Lipo-PGE1的男性住院患者明显多于女性,年龄61~75岁的患者最多。患者住院天数主要分布在8~14 d(45.01%),治疗结果以好转为主(68.20%)。Lipo-PGE1临床使用广泛,共涉及871种临床主要诊断,列前3位的是脑梗死(9.06%)、非胰岛素依赖型糖尿病(8.65%)和慢性缺血性心脏病(8.08%)。不同疾病和不同医院Lipo-PGE1的平均日剂量差异较大,且以≤12.5μg居多。结论:Lipo-PGE1作为辅助用药,需要医疗机构及相关监管部门制订合理的监管指标并加强用药指导及用药点评。
OBJECTIVE： To provide evidence for rational use and clinical monitoring of Alprostadil lipid-micro injection （Lipo-PGE,）. METHODS： Adult inpatients receiving Lipo-PGE1 from hospital information system （HIS） of 159 hospitals were selected as research subject. Based on frequency statistics, population, clinical diagnosis, and average daily dose of Lipo-PGEI were all studied. RESULTS： A total of 71 687 adult inpatients were included, and the male was more than female, mostly aged 61-75. The hospitalization duration was 8-14 d （45.01%）, most of patients were recovered （68.20%）. Lipo-PGE1 was wildly used in the clin- ic, and was used for 871 kinds of clinical diseases in total; top 3 diseases were cerebral infarction （9.06%）, non-insulin dependent diabetes meUitus （8.65%） and chronic ischemic heart disease （8.08%）. The average daily dose of different diseases and different hospitals were significantly different, mostly≤ 12.5μg. CONCLUSIONS： As adjuvant drug, medical institutions and related supervision departments should formulate reasonable monitoring index and strengthen medication guidance and evaluation of Lipo-PGE1.
出处
《中国药房》
CAS
北大核心
2017年第14期1903-1907,共5页
China Pharmacy
关键词
前列地尔脂微球注射剂
平均日剂量
合理用药
辅助用药
Alprostadil lipid-micro injection
Average daily dose
Rational use of drug
Adjuvant drug
